Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Preparation of blood components

Arthur J Silvergleid, MD
Section Editor
Steven Kleinman, MD
Deputy Editor
Jennifer S Tirnauer, MD


Blood components are those products derived from whole blood (or platelet-rich plasma) collected from normal donors by phlebotomy (or hemapheresis) using the technique of differential centrifugation. These products are prepared in blood centers or hospital laboratories, and should be distinguished from plasma derivatives, which are fractionated from large volumes (thousands of liters) of plasma in large, industrial manufacturing sites.

This topic review will discuss the preparation of blood components.

Use of these blood components is discussed separately.

Plasma – (See "Clinical use of plasma components".)

Red blood cells – (See "Red blood cell transfusion in adults: Storage, specialized modifications, and infusion parameters" and "Red blood cell transfusions in the newborn" and "Red blood cell transfusion in infants and children: Selection of blood products" and "Indications and hemoglobin thresholds for red blood cell transfusion in the adult".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2016. | This topic last updated: Sep 3, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Westphal RG. Donors and the United States blood supply. Transfusion 1997; 37:237.
  2. U.S. Department of Health and Human Services. The 2007 National Blood Collection and Utilization Survey, Washington, DC. DHHS, 2009.
  3. Heddle NM, Arnold DM, Boye D, et al. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48:1447.
  4. Skripchenko A, Myrup A, Thompson-Montgomery D, et al. Periods without agitation diminish platelet mitochondrial function during storage. Transfusion 2010; 50:390.
  5. Kerkhoffs JL, Eikenboom JC, Schipperus MS, et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108:3210.
  6. Committee on Standards, American Association of Blood Banks. Standards for Blood Banks and Transfusion Services, 26th ed, American Association of Blood Banks, Bethesda 2009.
  7. Kruskall MS. The perils of platelet transfusions. N Engl J Med 1997; 337:1914.
  8. Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007; 47:1134.
  9. Su LL, Kamel H, Custer B, et al. Bacterial detection in apheresis platelets: blood systems experience with a two-bottle and one-bottle culture system. Transfusion 2008; 48:1842.
  10. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008; 112:2617.
  11. Murphy WG, Foley M, Doherty C, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008; 95:13.
  12. Benjamin RJ, Kline L, Dy BA, et al. Bacterial contamination of whole-blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion 2008; 48:2348.
  13. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:1534.
  14. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426.
  15. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45:580.
  16. Murphy S, Snyder E, Cable R, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006; 46:24.
  17. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46:731.
  18. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48:1061.
  19. Vamvakas EC. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51:1058.
  20. Yazer MH, Cortese-Hassett A, Triulzi DJ. Coagulation factor levels in plasma frozen within 24 hours of phlebotomy over 5 days of storage at 1 to 6 degrees C. Transfusion 2008; 48:2525.
  21. von Heymann C, Keller MK, Spies C, et al. Activity of clotting factors in fresh-frozen plasma during storage at 4 degrees C over 6 days. Transfusion 2009; 49:913.
  22. Scott E, Puca K, Heraly J, et al. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage. Transfusion 2009; 49:1584.